1. Discontinuance or interruption in the production of life-saving devices (a) Notification requirement Section 506C of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c ) is amended— (1) in the section heading, by striking life-saving drugs and inserting life-saving drugs and devices ; (2) in the matter preceding paragraph (1) in subsection (a), by striking a drug and inserting a drug or device ; (3) in subsection (a)(1)(C), by striking such drug and inserting such drug or device ; (4) in the matter following paragraph (2) in subsection (a), by striking the drug each place it appears and inserting the drug or device ; (5) in subsection (c), by striking the drugs and inserting the drugs or devices ; (6) in the matter before paragraph (1) in subsection (g), by striking a drug shortage of a drug described in subsection (a) and inserting a drug or device shortage of a drug or device described in subsection (a) ; (7) in subsection (g)(1), by striking or a supplement to such an application submitted under section 505(j), that could help mitigate or prevent such shortage and inserting a supplement to such an application submitted under section 505(j), or a submission for clearance of a device under section 510(k), classification of a device under section 513(f)(2), or approval of a device under section 515, that could help mitigate or prevent such shortage ; (8) in subsection (g)(2), by striking such drug shortage and inserting such drug or device shortage ; (9) in subsection (h), by amending paragraph (2) to read as follows: (2) the term drug or device shortage or shortage , with respect to a drug or device, means a period of time when the demand or projected demand for the drug or device within the United States exceeds the supply of the drug or device; and